Pacira Pharmaceuticals Inc (PCRX)

35.70
0.60 1.65
NASDAQ : Health Care
Prev Close 36.30
Open 36.50
Day Low/High 35.35 / 36.50
52 Wk Low/High 31.08 / 80.25
Volume 601.41K
Avg Volume 688.70K
Exchange NASDAQ
Shares Outstanding 40.34M
Market Cap 1.49B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations At The Upcoming New York School Of Regional Anesthesia Annual Fall Symposium

Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations At The Upcoming New York School Of Regional Anesthesia Annual Fall Symposium

Studies evaluate impact of EXPAREL administered as a regional nerve block for both upper and lower extremity surgeries

Pacira Pharmaceuticals Stock Sees Short Interest Increase 53.8%

Pacira Pharmaceuticals Stock Sees Short Interest Increase 53.8%

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 1,627,603 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 4,650,854, an increase of 53.84% since 07/31/2017.

New Research Shows Vast Majority Of Oral Surgery Patients Would Choose Non-opioid Medication To Treat Postsurgical Pain If Given The Option

Patients and their parents willing to pay more for an opioid alternative following wisdom tooth extraction to avoid side effects and risk of addiction    

Short Interest In Pacira Pharmaceuticals Falls 19.5%

The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,240,223 share decrease in total short interest for Pacira Pharmaceuticals Inc. , to 5,113,726, a decrease of 19.52% since 02/28/2017.

First Week Of November 17th Options Trading For Pacira Pharmaceuticals (PCRX)

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the November 17th expiration.

Trinity Health And Pacira Pharmaceuticals Announce Collaboration To Decrease Opioid Use Nationwide

Collaboration will develop and standardize evidence-based, low-opioid strategies across Trinity Health's 22 states to benefit people and communities

Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira

Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira

Editas Medicine, Amphastar Pharmaceuticals, Aratana Therapeutics and Pacira Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

Pacira Pharmaceuticals Tops 4Q Earnings Expectations

Pacira Pharmaceuticals Tops 4Q Earnings Expectations

Pacira (PCRX) reported mixed fourth quarter results.

TheStreet Quant Rating: D+ (Sell)